10x GenomicsTXG +2.85%62 Current Ratio is 5.90 as of Mar. 2026, which is 10% above its 10-year median of 5.37. GuruFocus rates TXG with a GF Score™ of 62/100 and a GF Value™ of $19.00 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 683 Healthcare Providers & Services companies, 10x Genomics ranks better than 90.92% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. 10x Genomics's current ratio for the quarter that ended in Mar. 2026 was 5.90.
10x Genomics has a current ratio of 5.90. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for 10x Genomics's Current Ratio or its related term are showing as below:
TXG'
s Current Ratio Range Over the Past 10 Years
Min: 2.48 Med: 5.37 Max: 9.83
Current: 5.9
During the past 9 years, 10x Genomics's highest Current Ratio was 9.83. The lowest was 2.48. And the median was 5.37.
TXG's Current Ratio is ranked better than 90.92% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 1.47
vs TXG: 5.90
10x Genomics (NAS:TXG) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
10x Genomics Current Ratio Related Terms
10x Genomics Current Ratio Historical Data
* Premium members only.
The historical data trend for 10x Genomics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, 10x Genomics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics Current Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Current Ratio distribution charts can be found below:
* The bar in red indicates where 10x Genomics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics (TXG) has a Current Ratio of 5.90 as of Mar. 2026. This is 10% above median its historical median of 5.37. Over the past decade, 10x Genomics' Current Ratio has ranged from 2.48 to 9.83. According to the industry distribution chart, 10x Genomics ranks #62 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 9.1%.
Is 10x Genomics' Current Ratio too high?
10x Genomics' current Current Ratio of 5.90 is 10% above median its 10-year median of 5.37. Over the past 10 years, this metric has ranged from a low of 2.48 to a high of 9.83. The Healthcare Providers & Services industry median Current Ratio is 1.47. 10x Genomics' value of 5.90 is 301.4% above this industry median. Based on the distribution chart, 10x Genomics ranks #62 out of 683 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, 10x Genomics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Current Ratio compare to WAY and DOCS?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #62 out of 683 companies for Current Ratio. This places 10x Genomics in the top 9% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.47. 10x Genomics' value of 5.90 is 301.4% above this benchmark. Historically, 10x Genomics' own Current Ratio has ranged from 2.48 to 9.83 over the past decade. While the company's 10-year median is 5.37 vs. the industry median of 1.47, 10x Genomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Healthcare Providers & Services company?
The median Current Ratio among Healthcare Providers & Services companies is 1.47, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 10x Genomics's current Current Ratio of 5.90 is 301.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Current Ratio is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current Current Ratio is 5.90, which is 10% above median its own 10-year median of 5.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $19.00, compared to a current price of $36.70 — trading 93.2% above its estimated fair value. The current Current Ratio is 5.90, which is 10% above median its 10-year median of 5.37 and 301.4% above the Healthcare Providers & Services industry median of 1.47. 10x Genomics' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For 10x Genomics (TXG), the current Current Ratio is 5.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $36.70 is trading 93.2% above its estimated GF Value™ of $19.00.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
Current Ratio: 5.90 (10% above median its 10-year median of 5.37)
GF Value™: $19.00 vs. price of $36.70 (93.2% above fair value)
Industry Position: 301.4% above the Healthcare Providers & Services median (#62 of 683)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
62GF Score
Get the complete analysis for TXG
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
